Reducing Clinical Risk and Technical Risk Early with First-in-Human Study
SynerFuse™ is gathering safety, efficacy, and cost-effectiveness data in a first-in-human study to reduce clinical and technical risk in a fraction of the time of conventional Class III medical device start-ups.
Strategic Partnerships to Reduce Capital Requirement, Improve Time to Market and Increase Innovation
Strategic partnerships that bring together the necessary technical skills and technological innovations will enable SynerFuse™ to reduce R&D time by up to 75% and reduce capital needs by up to 80% over comparable startups.
Broad Patent Coverage to Enable Novel Innovation
SynerFuse™ has over 80 patents and published patent applications worldwide, across five international regions. The SynerFuse™ IP strategy protects key aspects of our concept and technology across the globe to enable our novel approach to solving chronic back pain.
